Kiniksa Pharmaceuticals (KNSA)

• Market cap: $2.22B
• 1 day: -1.02%
• 5 days: 11.21%
• 1 month: 8.64%
• 3 months: 11.46%
• 6 months: 51.21%
• Year to date: 50.75%
• 1 year: 13.52%
• 5 years: 53.21%
• 10 years: 54.39%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 18

15% more capital invested

Capital invested by funds: $772M [Q4 2024] → $888M (+$116M) [Q1 2025]

10% more funds holding

Funds holding: 159 [Q4 2024] → 175 (+16) [Q1 2025]

1.23% more ownership

Funds ownership: 93.91% [Q4 2024] → 95.15% (+1.23%) [Q1 2025]

6% more call options, than puts

Call options by funds: $2.7M | Put options by funds: $2.55M

4% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 57

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 40% upside
• Avg. target: $48 60% upside
• High target: $54 80% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Roger Song	80% upside $54	Buy Maintained	29 Jul 2025
Wells Fargo Eva Fortea Verdejo	40% upside $42	Overweight Maintained	9 Jul 2025